These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. Pinkas-Kramarski R, Lenferink AE, Bacus SS, Lyass L, van de Poll ML, Klapper LN, Tzahar E, Sela M, van Zoelen EJ, Yarden Y. Oncogene; 1998 Mar 12; 16(10):1249-58. PubMed ID: 9546426 [Abstract] [Full Text] [Related]
6. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. Ram TG, Dilts CA, Dziubinski ML, Pierce LJ, Ethier SP. Mol Carcinog; 1996 Mar 12; 15(3):227-38. PubMed ID: 8597535 [Abstract] [Full Text] [Related]
7. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH. EMBO J; 1997 Sep 15; 16(18):5608-17. PubMed ID: 9312020 [Abstract] [Full Text] [Related]
8. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor. Azios NG, Romero FJ, Denton MC, Doherty JK, Clinton GM. Oncogene; 2001 Aug 23; 20(37):5199-209. PubMed ID: 11526509 [Abstract] [Full Text] [Related]
11. ErbB kinases and NDF signaling in human prostate cancer cells. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ. Oncogene; 1997 Nov 27; 15(22):2705-16. PubMed ID: 9400997 [Abstract] [Full Text] [Related]
13. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y. EMBO J; 1996 Jan 15; 15(2):254-64. PubMed ID: 8617201 [Abstract] [Full Text] [Related]
14. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Grant SL, Hammacher A, Douglas AM, Goss GA, Mansfield RK, Heath JK, Begley CG. Oncogene; 2002 Jan 17; 21(3):460-74. PubMed ID: 11821958 [Abstract] [Full Text] [Related]
18. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G. Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466 [Abstract] [Full Text] [Related]
19. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo. Yang D, Kuan CT, Payne J, Kihara A, Murray A, Wang LM, Alimandi M, Pierce JH, Pastan I, Lippman ME. Clin Cancer Res; 1998 Apr 15; 4(4):993-1004. PubMed ID: 9563895 [Abstract] [Full Text] [Related]